Antitrombotic activity of a new benzimidazole derivative with a spatially difficult phenolic substitute in its structure
- Authors: Spasov A.A.1, Kucheryavenko A.F.1, Gaidukova K.A.1, Chernikov M.V.2, Zhukovskaya O.N.3
-
Affiliations:
- Volgograd State Medical University
- Pyatigorsk Medical and Pharmaceutical Institute – а branch of Volgograd State Medical University
- Research Institute of Physical and Organic Chemistry, Southern Federal University
- Issue: Vol 8, No 2 (2020)
- Pages: 78-85
- Section: Articles
- URL: https://journals.rcsi.science/2307-9266/article/view/111629
- DOI: https://doi.org/10.19163/2307-9266-2020-8-2-78-85
- ID: 111629
Cite item
Abstract
The aim of the study was to investigate antithrombogenic properties of compound RU-1144 with previously identified pronounced antiplatelet and antioxidant activities. The thrombosis induced by Ferric chloride (FeCl3) was carried out in rats’ carotid artery, in comparison with the known antiaggregant drugs – acetylsalicylic acid (ASA) and clopidogrel, as well as with the antioxidant preparation – ethylmethylhydroxypyridine succinate (EMHPS).
Materials and methods. The antithrombotic activity of compound RU-1144 was studied on the model of the rats with carotid artery thrombosis, induced by the application of 50% ferric chloride (FeCl3), and the Global Thrombosis Test model (the Görög Thrombosis Test). The evaluation of this type of activity was carried out by prolonging the time of a blood clot formation. The studies of the compound RU-1144 effect on the bleeding time parameter were performed in mice. Acetylsalicylic acid, clopidogrel and EMHPS were used as reference drugs.
Results. The antithrombotic effect of the RU-1144 substance revealed in the model of arterial thrombosis induced by the application of ferric chloride (FeCl3), exceeded that of both acetylsalicylic acid and clopidogrel by 3.5 times and that of EMHPS by 2.9 times. In the model of the in vitro Global Thrombosis Test (the Görög Thrombosis Test), compound RU-1144 reduced the thrombogenic potential of the blood equally with acetylsalicylic acid and clopidogrel. The assessment of “the bleeding time”, caused by the RU-1144 substance, showed that the prolongation of bleeding was twice as less pronounced than that caused by ASA and clopidogrel.
Conclusion. The performed studies demonstrated a pronounced antithrombotic activity of compound RU-1144, which exceeded that of acetylsalicylic acid, clopidogrel and EMHPS, while the ability to prolong the bleeding time was reliably lower than that of reference drugs.
Full Text
##article.viewOnOriginalSite##About the authors
Alexander A. Spasov
Volgograd State Medical University
Author for correspondence.
Email: aspasov@mail.ru
ORCID iD: 0000-0002-7185-4826
Doctor of Sciences (Medicine), Academician of the Russian Academy of Sciences, Professor, Head of the Department of Pharmacology and Bioinformatics
Russian Federation, 1, Pavshikh Bortsov Square, Volgograd, 400131Aida F. Kucheryavenko
Volgograd State Medical University
Email: aidakuchryavenko@yandex.ru
ORCID iD: 0000-0003-1406-6919
Doctor of Sciences (Medicine), Associate Professor, Professor of the Department of Pharmacology and Bioinformatics
Russian Federation, 1, Pavshikh Bortsov Square, Volgograd, 400131Ksenia A. Gaidukova
Volgograd State Medical University
Email: ksenijagajjdukva@rambler.ru
ORCID iD: 0000-0003-4376-6332
Assistant, the Department of Pharmacology and Bioinformatics
Russian Federation, 1, Pavshikh Bortsov Square, Volgograd, Russia, 400131Maxim V. Chernikov
Pyatigorsk Medical and Pharmaceutical Institute – а branch of Volgograd StateMedical University
Email: pharmax@list.ru
ORCID iD: 0000-0001-8340-1296
Doctor of Sciences (Medicine), the Head of the Department of Biology and Physiology
Russian Federation, 11, Kalinin av., Pyatigorsk, 357532Olga N. Zhukovskaya
Research Institute of Physical and Organic Chemistry, Southern Federal University
Email: zhukowskaia.ol@yandex.ru
ORCID iD: 0000-0003-0865-6656
Candidate of Sciences (Chemistry), Researcher at the Laboratory of Organic Synthesis
Russian Federation, 194, Bldg 2, Stachki Av., Rostov-on-Don, 344090References
- Papapanagiotou A, Siasos G, Gargalionis A, Papavassiliou AG. et al. The Role of Platelets in Cardiovascular Disease: Molecular Mechanisms. Curr Pharm Des. 2016;22(29):4493–505. doi: 10.2174/1381612822666160607064118
- Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Heart disease and stroke statistics (a report from the American Heart Association). Circulation. 2016;133:38–60. doi: 10.1161/CIR.0000000000000485
- Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction in women. Lancet. 2017;14(389): 197-210. doi: 10.1016/S0140-6736(16)00267-1
- Grove EL, Würtz M, Thomas MR, Kristensen SD. Antiplatelet therapy in acute coronary syndromes// Expert. Opin. Pharmacother. 2015;16(14):2133–47. doi: 10.1517/14656566.2015.1079619
- Shaturnyĭ VI, Shakhidzhanov SS, Sveshnikova AN, Panteleev MA. Activators, receptors and signal transduction pathways of blood platelets. Biomed Khim. 2014; 60(2):182–200. doi: 10.18097/pbmc20146002182
- Ambrosio D, Tritto I, GoIino P. Reactive oxygen metabolites and arterial thrombosis. Cardiovascular Research. 1998; 34:4445–524. doi: 10.1016/s0008-6363(97)00101-6.
- Aboonabia A, Singh I. The effectiveness of antioxidant therapy in aspirin resistance, diabetes population for the prevention of thrombosis. Biomedicine &Pharmacotherapy. 2016; 83: 277–2. doi: 10.1016/j.biopha.2016.06.044
- Chaschewic TV, Zhernosekov DD. Platelet aggregation. Mechanism of participation of adhesive molecules and mitochondria. Bulletin of Polessky State University. 2017: 51–61.
- Roka-Moya YM, et al. Novel aspects of platelet aggregation. Biopolym. cell. 2014. 30(1): 10. DOI: http: //dx.doi.org/10.7124/bc.000874
- Gordeev IG, Becchu EA, Lysov VA, Volov NA, Ilyin EE, et al. Evaluation of the effect of myocardial cytoprotectors on the processes of lipid peroxidation in patients with stable angina before and after surgical revascularization of the myocardium. Russian journal of cardiology. 2005; 3(53):41–6.
- Spasov AA, Kucheryavenko AF, Sirotenko VS, Gaidukova KA, Morkovnik AS, Anisimova VA, Divaeva LN, Kuzmenko TA. Antithrombotic activity of a new derivative of diazepinobenzimidazole compound DAB-15. Bulletin of experimental biology and medicine. 2016; 162(11):585–8.
- Spasov AA, Kucheryavenko AF, Kosolapov VA, Anisimova VA. Antithrombogenic activity of antioxidant compounds. Bulletin of experimental biology and medicine. 2013. 155(6):740–2.
- Kosolapov VA, Spasov AA, Аnisimova VА, Zhukovskaya ON. Condensed Benzimidazoles Are a Novel Scaffold for Antioxidant Agents’ Search and Development. Antioxidants. 2019: 245–53. doi: 10.5772/intechopen.82817
- Spasov AA, Nedogoda VV, Konan K, Kucheryavenko AF. Mechanism of reduction of platelet sensitivity to medicines in response to low-energy laser radiation of blood. Hematology and transfusiology. 2001; 46(2):36–9.
- Makarov VA, Spassov AA, Plotnikov MB, Belozerskaya GG, Vasileva TM, et al. Guidelines for the study of drugs that affect hemostasis. In the book: a Guide to preclinical trials of medicinal products of the fgbi “NCESMP” health Ministry of Russia. Moscow. 2012: 453–79.
- Zhitnikova LM. ASA in the prevention and treatment of cardiovascular disease: clinical guidelines for practitioners. Regular issues of “BC”. Cardiology. 2012;14:708–13
- Kurz KD, Main BW, Sandusky GE. rat model of arterial thrombosis induced by ferric chloride. Thromb Res. 1990;15:269–80. doi: 10.1016/0049-3848(90)90106-m
- Yamamoto J, Inoue N. et al. Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential. Thrombosis Research. 2014;133: 919-26. doi: 10.1016/j.thromres.2014.02.018
- Greene TK, Schiviz A. et al. Towards a standardization of the murine tail bleeding model//J. Thromb Haemost. 2010;8(12):2820-2. doi: 10.1111/j.1538-7836.2010.04084.x
- Haber F, Weiss J. On the catalysis of hydroperoxide. Naturwissenschaften. 1932;20:948–50.
- Freedman JE. Oxidative Stress and Platelets. Arteriosclerosis, Thrombosis and Vascular Biology. 2008;28:11-6. doi: 10.1161/ATVBAHA.107.159178. Epub 2008 Jan 3.
- Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180–3. doi: 10.1016/j.redox.2015.01.002
- Dogne JM, Hanson J, Leval X, et al. Pharmacological characterization of N-tert-Butyl-N-[2-(4-methylphenylamino)-5-nitrobenzenesulfonyl] urea (BM-5730, a novel Thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time. J of Pharmacol and Exp Therap. 2004;309:498–505. doi: 10.1124/jpet.103.063610
- Buccheri S, Capodanno D, James S, Angiolillo DJ. Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. Expert Opin Drug Saf. 2019;25:1–19. DOI: 10.1080 / 14740338.2019.1680637.
- Qiu L, Han JX, See AAQ, King NKK. Effects of anticoagulant and antiplatelet agents in severe traumatic brain injury in an Asian population – A matched case-control study. J Clin Neurosci. 2019:61–6. DOI: 10.1016 / j.jocn.2019.08.08.087.
- Spasov AA, Kucheryavenko AF, Tien M, Anisimova VA. Antithrombotic activity of the compound RU-891. Experimental and Clinical Pharmacology. 2013;76(6):25–6. DOI: https: // doi.org/10.30906/0869-2092-2013-76-6-25-26
- Spronk HMH., Padro T, Siland JE. Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis. ThrombHaemost. 2018;118(118):229–50. DOI: 10.1160 / TH17-07-0492
- Dadjou Y, Safavi S, Javad K. Risks and Benefits of Dual Antiplatelet Therapy Beyond 12 Months After Coronary Stenting. Medicine (Baltimore). 2016;95(22):1–7. DOI: 10.1097 / MD.0000000000003663
- Shakhmardanova SA, Gulevskaya ON, Seletskaya VV, Zelenskaya AV, et al. Antioxidants: classification, pharmacotherapeutic properties, use in practical medicine. Journal of Fundamental Medicine and Biology. 2016;3:4–12.
- Bath PM, May J, Heptinstall S. Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders. Platelets. 2018. 29(5):425–30. DOI: 10.1080 / 09537104.2018.1445839
- Spasov AA, Kucheryavenko AF, Gaidukova KA, Kosolapov VA, Zhukovskaya ON. Antiplatelet activity of new derivatives of benzimidazole containing sterically hindered phenolic group in their structure. Research Results in Pharmacology. 2020;6(1):1–9. DOI: 10.3897 / rrpharmacology.6.50373